NCT06491719View on ClinicalTrials.gov

A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT

NANot yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2026

Conditions
CAEBV (Chronic Active Epstein-Barr Virus Infection) SyndromeEBVHemophagocytic Lymphohistiocytoses
Interventions
OTHER

NCR300（Allogenic Ipsc-derived Natural Killer cells ）

"Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit."

Trial Locations (1)

Unknown

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Friendship Hospital

OTHER

NCT06491719 - A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT | Biotech Hunter | Biotech Hunter